9.4 C
New York
Sunday, December 3, 2023

What Are The Chances Of Clover Health Investments Corp (NASDAQ: CLOV) Becoming A Clear Buy?

After Hours

There may be slightly higher risks associated with pre-market and after-hours trading than during regular market hours. Due to the fact that issuers often announce critical financial information outside of regular trading hours, extended-hours trading may result in wider spreads for particular securities. After-hours trades for Clover Health Investments Corp (CLOV) shows that investor sentiment remained broken, with the stock’s consolidated last price falling by -$0.01, or -0.98%, to $1.01. The Clover Health Investments Corp has recorded 11,657 volume in the after hours trading session. The stock was recently discussed on Yahoo Finance as it revealed that Clover Health and WellBe Senior Medical Partner to Bring In-home Medical Care to Atlanta Patients and Across Rural Georgia.

Top 5 EV Tech Stocks to Buy for 2023

The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".

Click Here to Download the FREE Report.


Stocks Info

As a NASDAQ listed company, CLOV falls under the Healthcare sector while operating within the Healthcare Plans industry segment. At the end of the last regular session, the stock closed at $1.02 and fluctuated between $1.0600 as its day high and $1.0000 as its day low. The current market capitalization of Clover Health Investments Corp is $497.39M. A total of 3.21 million shares were traded on the day, compared to an average of 4.04M shares.

Aside from predicting where a stock will go, investors also consider insider trades as an indicator of the stock’s future direction. During the recent three months, CLOV has seen 11 BUY and 6 SELL insider trades, representing the acquisition of 4,762,202 and the disposition of 440,819 shares. Over the last 12 months, there were 20 BUYs and 18 SELLs from insiders. Insiders purchased 15,949,228 shares during that period but sold 1,799,897.

In the most recent transaction, Loengard Anna U bought 11,000 shares of CLOV for 1.30 per share on Sep 06. After the transaction, the Director now owns 10,000 company shares.

In spite of price targets being rarely accurate, it tends to exert some kind influence from time to time, and was often accepted by the market as having some value. According to analysts who have offered 12-month price targets for CLOV in the last 3 months, the mean price target is $1.33 with high estimates of $2.00 and low estimates of $1.00. In terms of 52-week highs and lows, CLOV has a high of $1.63 and a low of $0.71.

As of this writing, CLOV has an earnings estimate of -$0.16 per share for the current quarter. EPS was calculated based on a consensus of 2 estimates, with a high estimate of -$0.14 per share and a lower estimate of -$0.18. The company reported an EPS of -$0.06 in the last quarter, which was 60.00% higher than expectations of -$0.15.

Balance Sheet Annually/Quarterly

The balance sheet of a company shows what assets and liabilities a company has, as well as the amount, equity investors have invested. With the help of this information, a company’s financial ratios can be calculated to give investors an overview of the company’s prospects. CLOV’s latest balance sheet shows that the firm has $791.19M in Cash & Short Term Investments as of fiscal 2021. There were $27.83M in debt and $372.62M in liabilities at the time. Its Book Value Per Share was $0.67, while its Total Shareholder’s Equity was $539.32M.

Analysts Opinion

The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for CLOV is Buy with a score of 3.25.

Related Articles


Please enter your comment!
Please enter your name here

Latest Articles